St. John's Wort, Rx Drug Use Warning Adopted By CHPA
This article was originally published in The Tan Sheet
Consumer Healthcare Products Association member companies soon will be incorporating a prescription drug use warning on their St. John's wort supplements.
You may also be interested in...
The Consumer Healthcare Products Association has adopted a voluntary program for member companies producing kava kava supplements to include a label warning about the botanical's ability to induce drowsiness.
Guidances recommending cautionary statements on the labeling of St. John's wort and saw palmetto products were adopted recently by the American Herbal Products Association's Board of Trustees.
Numerous dietary supplements, including coenzyme Q10 and dong quai, may cause adverse events due to possible interactions with the Rx anticoagulant warfarin, an article in the July 1 American Journal of Health-System Pharmacy notes.